Pelthos Therapeutics has announced the appointment of John M. Gay as Chief Financial Officer, effective April 10, 2026. Gay succeeds Francis Knuettel II and brings over 25 years of finance experience to the role
Who to call at Pelthos Therapeutics, and when
A new leader at Pelthos Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Pelthos Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Pelthos Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pelthos Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Pelthos Therapeutics
Location
Durham, North Carolina, United States
About
Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections. The company is known for its FDA-approved drug ZELSUVMI, which is the first prescription treatment for home use. Pelthos is committed to advancing patient care through innovative therapeutic solutions. It operates as a subsidiary of Ligand Pharmaceuticals.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pelthos Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
DurhamBiotechnologyHealth CareTherapeuticsPharmaceutical